Joseph Chen

Dr. Joseph Chen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJoseph Chen
Joseph Chen
BABadriprasad Ananthanarayanan
Badriprasad Ananthanarayanan
KSKelsey S. Springer
Kelsey S. Springer
KWKayla J. Wolf
Kayla J. Wolf
SSSharon M. Sheyman
Sharon M. Sheyman
SKSanjay Kumar
Sanjay Kumar
The aggressive brain tumor glioblastoma (GBM) is characterized by rapid cellular infiltration of brain tissue, raising the possibility that disease progression could potentially be slowed by disrupting the machinery of cell migration. The LIM kinase isoforms LIMK1 and LIMK2 (LIMK1/2) play important roles in cell polarization, migration, and invasion and are markedly upregulated in GBM and many other infiltrative cancers. Yet, it remains unclear whether LIMK suppression could serve as a viable basis for combating GBM infiltration. In this study, we investigated effects of LIMK1/2 suppression on GBM invasion by combining GBM culture models, engineered invasion paradigms, and mouse xenograft models. While knockdown of either LIMK1 or LIMK2 only minimally influenced invasion in culture, simultaneous knockdown of both isoforms strongly reduced the invasive motility of continuous culture models and human GBM tumor-initiating cells (TIC) in both Boyden chamber and 3D hyaluronic acid spheroid invasion assays. Furthermore, LIMK1/2 functionally regulated cell invasiveness, in part, by disrupting polarized cell motility under confinement and cell chemotaxis. In an orthotopic xenograft model, TICs stably transduced with LIMK1/2 shRNA were implanted intracranially in immunocompromised mice. Tumors derived from LIMK1/2 knockdown TICs were substantially smaller and showed delayed growth kinetics and more distinct margins than tumors derived from control TICs. Overall, LIMK1/2 suppression increased mean survival time by 30%. These findings indicate that LIMK1/2 strongly regulate GBM invasive motility and tumor progression and support further exploration of LIMK1/2 as druggable targets. Significance: Targeting the actin-binding proteins LIMK1 and LIMK2 significantly diminishes glioblastoma invasion and spread, suggesting the potential value of these proteins as therapeutic targets.

15 September 2021 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
JCJoseph Chen
Joseph Chen
HLHyunchul Lee
Hyunchul Lee
PSPhilipp Schmitt
Philipp Schmitt
CCCaleb J Choy
Caleb J Choy
DMDonald M Miller
Donald M Miller
HFHermann B Frieboes
Hermann B Frieboes
Despite extensive research and aggressive therapies, glioblastoma (GBM) remains a central nervous system malignancy with poor prognosis. The varied histopathology of GBM suggests a landscape of differing microenvironments and clonal expansions, which may influence metabolism, driving tumor progression. Indeed, GBM metabolic plasticity in response to differing nutrient supply within these microenvironments has emerged as a key driver of aggressiveness. Additionally, emergent biophysical and biochemical interactions in the tumor microenvironment (TME) are offering new perspectives on GBM metabolism. Perivascular and hypoxic niches exert crucial roles in tumor maintenance and progression, facilitating metabolic relationships between stromal and tumor cells. Alterations in extracellular matrix and its biophysical characteristics, such as rigidity and topography, regulate GBM metabolism through mechanotransductive mechanisms. This review highlights insights gained from deployment of bioengineering models, including engineered cell culture and mathematical models, to study the microenvironmental regulation of GBM metabolism. Bioengineered approaches building upon histopathology measurements may uncover potential therapeutic strategies that target both TME-dependent mechanotransductive and biomolecular drivers of metabolism to tackle this challenging disease. Longer term, a concerted effort integrating in vitro and in silico models predictive of patient therapy response may offer a powerful advance toward tailoring of treatment to patient-specific GBM characteristics.

24 June 2024 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
BMBradley J. Mahaffey
Bradley J. Mahaffey
ZFZachary P. Fowler
Zachary P. Fowler
ZLZoe Lung
Zoe Lung
VDVivien Dang
Vivien Dang
HLHyunchul Lee
Hyunchul Lee
JCJoseph Chen
Joseph Chen
Glioblastoma (GBM) is a highly invasive, aggressive brain cancer that carries a median survival of 15 months and is resistant to standard therapeutics. Recent studies have demonstrated that intratumoral heterogeneity plays a critical role in promoting resistance by mediating tumor adaptation through microenvironmental cues. GBM can be separated into two distinct regions—a core and a rim, which are thought to drive specific aspects of tumor evolution. These differences in tumor progression are regulated by the diverse biomolecular and biophysical signals in these regions, but the acellular biophysical characteristics remain poorly described. This study investigates the mechanical and ultrastructural characteristics of the tumor extracellular matrix (ECM) in patient-matched GBM core and rim tissues. Seven patient-matched tumor core and rim samples and one non-neoplastic control were analyzed using atomic force microscopy, scanning electron microscopy, and immunofluorescence imaging to quantify mechanical, ultrastructural, and ECM composition changes. The results reveal significant differences in biophysical parameters between GBM core, rim, and non-neoplastic tissues. The GBM core is stiffer, denser, and is rich in ECM proteins hyaluronic acid and tenascin-C when compared to tumor rim and non-neoplastic tissues. These alterations are intimately related and have prognostic effect with stiff, dense tissue correlating with longer progression-free survival. These findings reveal new insights into the spatial heterogeneity of biophysical parameters in the GBM tumor microenvironment and identify a set of characteristics that may correlate with patient prognosis. In the long term, these characteristics may aid in the development of strategies to combat therapeutic resistance.

9 April 2025 in Frontiers in Materials
Verified
Journal Article
Open access
PDF file
AJAllison McKenzie Johnson
Allison McKenzie Johnson
CFCharles Froman-Glover
Charles Froman-Glover
AMAkshitkumar Mistry
Akshitkumar Mistry
KYKavitha Yaddanapudi
Kavitha Yaddanapudi
JCJoseph Chen
Joseph Chen
Cancer is one of the deadliest diseases despite aggressive therapeutics. This is due in part to the evolving tumor microenvironment (TME), which provide tumor supportive cues that promote tumor adaptation and progression. Emerging studies highlight the significant role of the biophysical characteristics in the TME in modulating all aspects of cancer aggressive and spread. With the advance of bioengineering platforms, deeper investigations into the impact of these biophysical features on cancer progression are being conducted with a growing appreciation of the intratumoral compression that underlie many of the biophysical changes. Intratumoral compression emerges early in tumor development and increases in magnitude as the tumor rapidly expands against itself and its surrounding tissue. This stress has effects on both the cancer cells and biophysical aspects of the TME, including hypoxia, shear stress, extracellular matrix (ECM) remodeling, and substrate stiffness. This creates a physically dense, pro-malignant environment that can both promote metastatic phenotypes and spread but also present biophysical barriers for immune cell infiltration. This review will analyze the effect of compressive stress on the TME, cancer cells, and on confined migration of cancer and immune populations.

23 February 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
AMAkshitkumar Mistry
Akshitkumar Mistry
JDJonah Daneshmand
Jonah Daneshmand
SSSeonYeong Jamie Seo
SeonYeong Jamie Seo
NLNorman L. Lehman
Norman L. Lehman
DMDonald M. Miller
Donald M. Miller
KYKavitha Yaddanapudi
Kavitha Yaddanapudi
Background: Glioblastoma (GBM) tumors are rich in tumor-associated microglia/macrophages. Changes associated with treatment in this specific cell population are poorly understood. Therefore, we studied changes in gene expression of tumor-associated microglia/macrophages (Iba1+) cells in de novo versus recurrent GBMs. Methods: NanoString GeoMx® Digital Spatial Transcriptomic Profiling of microglia/macrophages (Iba1+) and glial cells (Gfap+) cells identified on tumor sections was performed on paired de novo and recurrent samples obtained from three IDH-wildtype GBM patients. The impact of differentially expressed genes on patient survival was evaluated using publicly available data. Results: Unsupervised analyses of the NanoString GeoMx® Digital Spatial Profiling data revealed clustering based on the transcriptomic data from Iba1+ and Gfap+ cells. As expected, conventional differential gene expression and enrichment analyses revealed upregulation of immune-function-related genes in Iba1+ cells compared to Gfap+ cells. A focused differential gene expression analysis revealed upregulation of phagocytosis and fatty acid/lipid metabolism genes in Iba1+ cells in recurrent GBM samples compared to de novo GBM samples. Importantly, of these genes, the lipid metabolism gene PLD3 consistently correlated with survival in multiple different publicly available datasets. Conclusion: Tumor-associated microglia/macrophages in recurrent GBM overexpress genes involved in fatty acid/lipid metabolism. Further investigation is needed to fully delineate the role of PLD phospholipases in GBM progression.

18 January 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
LTLandon Teer
Landon Teer
KYKavitha Yaddanapudi
Kavitha Yaddanapudi
JCJoseph Chen
Joseph Chen
GBM is the most aggressive and common form of primary brain cancer with a dismal prognosis. Current GBM treatments have not improved patient survival, due to the propensity for tumor cell adaptation and immune evasion, leading to a persistent progression of the disease. In recent years, the tumor microenvironment (TME) has been identified as a critical regulator of these pro-tumorigenic changes, providing a complex array of biomolecular and biophysical signals that facilitate evasion strategies by modulating tumor cells, stromal cells, and immune populations. Efforts to unravel these complex TME interactions are necessary to improve GBM therapy. Immunotherapy is a promising treatment strategy that utilizes a patient’s own immune system for tumor eradication and has exhibited exciting results in many cancer types; however, the highly immunosuppressive interactions between the immune cell populations and the GBM TME continue to present challenges. In order to elucidate these interactions, novel bioengineering models are being employed to decipher the mechanisms of immunologically “cold” GBMs. Additionally, these data are being leveraged to develop cell engineering strategies to bolster immunotherapy efficacy. This review presents an in-depth analysis of the biophysical interactions of the GBM TME and immune cell populations as well as the systems used to elucidate the underlying immunosuppressive mechanisms for improving current therapies.